Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
Author:
Open Access
- 26 April 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 454
Abstract
Immune-related hematological adverse events are amongst the rare but potentially life-threatening complications of immune checkpoint inhibitors. The spectrum of these toxicities is broadening as the number of patients exposed to these agents is increasing. Yet, they are still relatively unknown to many clinicians, possibly due to a lack of specific diagnostic criteria, which poses a challenge for their recognition and proper reporting, and partly due to their low incidence, often too low to be noted in most clinical trial publications. Since early detection and prompt intervention are crucial to prevent fatal consequences, it is of outmost importance that medical staff and patients be aware of these potential toxicities and learn to recognize and treat them adequately. This publication outlines strategies and offers guidance on the detection, diagnosis, risk assessment, monitoring and management of immune-related thrombocytopenia, a relatively common example of immune-related hematological toxicity of immune checkpoint inhibitors.Keywords
This publication has 57 references indexed in Scilit:
- Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanomaExperimental Hematology & Oncology, 2012
- More on Hemophilia A Induced by IpilimumabNew England Journal of Medicine, 2012
- Hemophilia A Induced by IpilimumabNew England Journal of Medicine, 2011
- Ipilimumab-induced thrombocytopenia in a patient with metastatic melanomaJournal of Oncology Pharmacy Practice, 2011
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)Cancer Immunology, Immunotherapy, 2010
- Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)Journal of Immunotherapy, 2009
- Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working groupBlood, 2009
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaCancer Immunology, Immunotherapy, 2008